Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-cash Items (2017 - 2024)

Historic Non-cash Items for Protalix BioTherapeutics (PLX) over the last 8 years, with Q4 2024 value amounting to $1.0 million.

  • Protalix BioTherapeutics' Non-cash Items fell 6153.85% to $1.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year decrease of 6153.85%. This contributed to the annual value of $1.0 million for FY2024, which is 6153.85% down from last year.
  • According to the latest figures from Q4 2024, Protalix BioTherapeutics' Non-cash Items is $1.0 million, which was down 6153.85% from $2.6 million recorded in Q4 2023.
  • Protalix BioTherapeutics' 5-year Non-cash Items high stood at $2.6 million for Q4 2023, and its period low was $702889.0 during Q4 2020.
  • Its 5-year average for Non-cash Items is $1.4 million, with a median of $1.0 million in 2024.
  • In the last 5 years, Protalix BioTherapeutics' Non-cash Items skyrocketed by 7999.4% in 2022 and then crashed by 6153.85% in 2024.
  • Protalix BioTherapeutics' Non-cash Items (Quarter) stood at $702889.0 in 2020, then soared by 36.86% to $961940.0 in 2021, then surged by 79.99% to $1.7 million in 2022, then soared by 50.16% to $2.6 million in 2023, then plummeted by 61.54% to $1.0 million in 2024.
  • Its Non-cash Items stands at $1.0 million for Q4 2024, versus $2.6 million for Q4 2023 and $1.7 million for Q4 2022.